These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 30280286)

  • 1. A Gyrolab Assay for the Quantitation of Free Complement Protein C5a in Human Plasma.
    Dysinger M; Ma M
    AAPS J; 2018 Oct; 20(6):106. PubMed ID: 30280286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eculizumab-C5 complexes express a C5a neoepitope in vivo: Consequences for interpretation of patient complement analyses.
    Nilsson PH; Thomas AM; Bergseth G; Gustavsen A; Volokhina EB; van den Heuvel LP; Barratt-Due A; Mollnes TE
    Mol Immunol; 2017 Sep; 89():111-114. PubMed ID: 28610663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A sensitive enzyme immunoassay for the quantitation of human C5a/C5a(desArg) anaphylatoxin using a monoclonal antibody with specificity for a neoepitope.
    Oppermann M; Schulze M; Götze O
    Complement Inflamm; 1991; 8(1):13-24. PubMed ID: 1710957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing NBE PK/PD assays using the Gyrolab Affinity Software; conveniently within the bioanalyst's existing workflow.
    Myzithras M; Bigwarfe T; Waltz E; Li H; Ahlberg J; Rybina I; Low S; Kenny CH; Miglietta J; Kroe-Barrett R
    Bioanalysis; 2018 Mar; 10(6):397-406. PubMed ID: 29451404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of miniaturized immunoassays to discovery pharmacokinetic bioanalysis.
    Roman J; Qiu J; Dornadula G; Hamuro L; Bakhtiar R; Verch T
    J Pharmacol Toxicol Methods; 2011; 63(3):227-35. PubMed ID: 21147239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of bioanalytical methods for the quantitation of PEGylated human insulin.
    de Dios K; Manibusan A; Marsden R; Pinkstaff J
    J Immunol Methods; 2013 Oct; 396(1-2):1-7. PubMed ID: 23933323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid quantification of C3a and C5a using a combination of chromatographic and immunoassay procedures.
    Hartmann H; Lübbers B; Casaretto M; Bautsch W; Klos A; Köhl J
    J Immunol Methods; 1993 Nov; 166(1):35-44. PubMed ID: 7693822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A sensitive ELISA for the quantitation of human C5a in blood plasma using a monoclonal antibody.
    Schulze M; Götze O
    Complement; 1986; 3(1):25-39. PubMed ID: 3743034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-neutralization of C5a-mediated effects by the monoclonal antibody 137-26 reacting with the C5a moiety of native C5 without preventing C5 cleavage.
    Fung M; Lu M; Fure H; Sun W; Sun C; Shi NY; Dou Y; Su J; Swanson X; Mollnes TE
    Clin Exp Immunol; 2003 Aug; 133(2):160-9. PubMed ID: 12869020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of complement fragment C5a in milk is variable among cows.
    Rainard P; Poutrel B
    J Dairy Sci; 2000 May; 83(5):945-51. PubMed ID: 10821569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New concepts on the therapeutic control of complement anaphylatoxin receptors.
    Hawksworth OA; Li XX; Coulthard LG; Wolvetang EJ; Woodruff TM
    Mol Immunol; 2017 Sep; 89():36-43. PubMed ID: 28576324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of native human complement components C3 and C5 and their primary activation peptides C3a and C5a (anaphylatoxic peptides) by ELISAs with monoclonal antibodies.
    Klos A; Ihrig V; Messner M; Grabbe J; Bitter-Suermann D
    J Immunol Methods; 1988 Jul; 111(2):241-52. PubMed ID: 3260926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantification of C5a/C5a(desArg) in bovine plasma, serum and milk.
    Rainard P; Sarradin P; Paape MJ; Poutrel B
    Vet Res; 1998; 29(1):73-88. PubMed ID: 9559522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement component 5a (C5a).
    Manthey HD; Woodruff TM; Taylor SM; Monk PN
    Int J Biochem Cell Biol; 2009 Nov; 41(11):2114-7. PubMed ID: 19464229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controlling the anaphylatoxin C5a in diseases requires a specifically targeted inhibition.
    Riedemann NC; Habel M; Ziereisen J; Hermann M; Schneider C; Wehling C; Kirschfink M; Kentouche K; Guo R
    Clin Immunol; 2017 Jul; 180():25-32. PubMed ID: 28366510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cleavage of the fifth component of human complement and release of a split product with C5a-like activity by crystalline silica through free radical generation and kallikrein activation.
    Governa M; Fenoglio I; Amati M; Valentino M; Bolognini L; Coloccini S; Volpe AR; Carmignani M; Fubini B
    Toxicol Appl Pharmacol; 2002 Mar; 179(3):129-36. PubMed ID: 11906242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Staphylococcus aureus-induced complement activation promotes tissue factor-mediated coagulation.
    Skjeflo EW; Christiansen D; Fure H; Ludviksen JK; Woodruff TM; Espevik T; Nielsen EW; Brekke OL; Mollnes TE
    J Thromb Haemost; 2018 May; 16(5):905-918. PubMed ID: 29437288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of a Gyrolab™ assay for quantification of rituximab in human serum.
    Liu XF; Wang X; Weaver RJ; Calliste L; Xia C; He YJ; Chen L
    J Pharmacol Toxicol Methods; 2012; 65(3):107-14. PubMed ID: 22406436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Both plasma- and leukocyte-associated C5a are essential for assessment of C5a generation in vivo.
    Hetland G; Moen O; Bergh K; Högäsen K; Hack CE; Mollnes TE; Fosse E
    Ann Thorac Surg; 1997 Apr; 63(4):1076-80. PubMed ID: 9124908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gyrolab Immunoassays: Miniaturization, Automation, and Integration into a Rapid Workflow.
    Engström J
    Methods Mol Biol; 2023; 2612():109-127. PubMed ID: 36795363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.